Intensive and Critical Care Nursing
Volume 22, Issue 1 , Pages 59-62 , February 2006

Caspofungin in the treatment of invasive fungal infections

  • Simon Keady

      Affiliations

    • Women and Children's Services, University College London Hospitals NHS Foundation Trust, UK
    • Corresponding Author InformationCorresponding author.
    • ,
  • Meera Thacker

      Affiliations

    • Critical Care Services, Royal Free Hampstead NHS Trust, UK

Received 4 May 2005 ,Accepted 10 May 2005.

References 

  1. Castagnola E, Machetti M, Cappelli B, et al. Caspofungin associated with liposomal amphotericin B or voriconazole for treatment of refractory fungal pneumonia in children with acute leukaemia or undergoing allogenic bone marrow transplant. Clin Microbiol Infect. 2004;10(3):255–257
  2. Maertens J, Raad I, Petrikkos G, et al. Update of the multicenter noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to amphotericin B. In: 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego. 2002, September 27–30;
  3. Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(December (25)):2020–2029
  4. Odio C, Araya R, Pinto L, et al. Caspofungin therapy of neonates with invasive candidiasis. Pediatr Infect Dis J. 2004;23(12):1093–1097
  5. Villanueva A, Arathoon EG, Gotuzzo E, et al. A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Clin Infect Dis. 2001;33(November (9)):1529–1535
  6. Villanueva A, Gotuzzo E, Arathoon EG, et al. A randomized double-blind study of caspofungin versus fluonazole for the treatment of candidal esophagitis. Am J Med. 2002;113(September (4)):294–299

PII: S0964-3397(05)00062-5

doi: 10.1016/j.iccn.2005.05.003

Intensive and Critical Care Nursing
Volume 22, Issue 1 , Pages 59-62 , February 2006

Article Tools